Sandra Sigala

18PUBLICATIONS
68CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyInstrumental methods (excl. immunological and bioassay methods)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 05, 2026
Prognostic role of pretreatment [<sup>18</sup>F]FDG PET/CT in patients affected by adrenocortical carcinoma and treated with chemotherapy.

Francesco Dondi, Davide Lorenzo Bettini, Deborah Cosentini

|Nov 11, 2024
Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas.

Emanuela Esposito, Giusy Marra, Rosa Catalano

|Aug 20, 2024
A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples.

Yasuhiro Arakawa, Fathi Elloumi, Sudhir Varma

|Mar 13, 2024
The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.

Elisa Rossini, Mariangela Tamburello, Andrea Abate

|Sep 28, 2023
Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status.

Antonella Turla, Marta Laganà, Andrea Abate

|Sep 28, 2023
Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. <i>Cells</i> 2022, <i>11</i>, 1439.

Sandra Sigala, Christina Bothou, David Penton

Pageof 3

Frequent Collaborators

11 joint publications

Guido Alberto Massimo Tiberio

7 joint publications

Alfredo Berruti

6 joint publications

Alfredo Berruti

6 joint publications

Salvatore Grisanti